Jul 2 |
US Equities Markets End Higher Tuesday Following Fed Chair Powell's Comments
|
Jul 2 |
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
|
Jul 2 |
Biogen Completes Acquisition of Human Immunology Biosciences
|
Jul 1 |
10 clinical trials to watch in the second half of 2024
|
Jun 28 |
Biogen, Eisai launch Alzheimer's drug Leqembi in China
|
Jun 28 |
Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
|
Jun 28 |
Eisai and Biogen launch Alzheimer's drug Leqembi in China
|
Jun 27 |
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
|
Jun 26 |
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
|
Jun 26 |
Pharma M&A: The top high value deals in 2023
|